Cedrik Michael Britten

7PUBLICATIONS
68CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 19, 2026
Author Correction: MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

|May 31, 2026
MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial.

|Dec 18, 2025
Dysfunctional CD4 T cells in an oncovirus-specific TCR-transgenic in vivo model.

Felicia S Spitzer, Marcel G M Camps, Cedrik M Britten

|Apr 29, 2025
Author Correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.

Martin Wermke, Dejka M Araujo, Manik Chatterjee

|Apr 09, 2025
Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial.

Martin Wermke, Dejka M Araujo, Manik Chatterjee

|May 12, 2023
Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer.

Apostolia M Tsimberidou, Kerstin Guenther, Borje S Andersson

Pageof 2

Frequent Collaborators

5 joint publications

Norbert Hilf

4 joint publications

Martin Wermke

3 joint publications

Carsten Reinhardt

3 joint publications

Manuel Ruh